[Importance of PPSB fraction in the treatment of hemophilia A with antibodies against factor VIII].
On the basis of the indirectly established statement that activated forms of the coagulation factor are also present in PPSB fractions of own production, the activated concentrate of factor IX and of the prothrombin complex were applied in haemophilia-A patients with antibodies against factor VIII. The fraction was administered to 4 patients during 14 bleeding times, mostly during bleedings of joints an soft tissues, twice during haematuria in a dose of 40-200 E-factor IX per kg of body weight and per day. The total dose was mainly administered in a fractionized way at an interval of 8 or 12 hours. This treatment lasted for 2 to 7 days. With regard to haemostasis no fundamental improvement of global blood coagulation tests (which have pathological results in haemophilia-A patients) could be identified in the course of the treatment. However, the increase of factor II, VII, and X in the patient's plasma was striking. Contrary to exceptations, there was a less distinct increase of factor IX activity. Concluding from these findings it may be assumed that the "strengthening" of the "extrinsic system" is decisive for the haemostatic effect in the treatment mentioned.
D001777:Blood Coagulation; D001779:Blood Coagulation Factors / Q000032:analysis; D005164:Factor IX / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology; D006467:Hemophilia A / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D008297:Male; D011516:Prothrombin / Q000627:therapeutic use*
D001779:Blood Coagulation Factors; D011516:Prothrombin; D005169:Factor VIII; D005164:Factor IX
Die Bedeutung der PPSB-Fraktion in der Behandlung der Hämophilie A mit Antikörpern gegen Faktor VIII.